

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 FEB 27 New STN AnaVist pricing effective March 1, 2006  
NEWS 4 MAY 10 CA/CAPLUS enhanced with 1900-1906 U.S. patent records  
NEWS 5 MAY 11 KOREAPAT updates resume  
NEWS 6 MAY 19 Derwent World Patents Index to be reloaded and enhanced  
NEWS 7 MAY 30 IPC 8 Rolled-up Core codes added to CA/CAPLUS and  
USPATFULL/USPAT2  
NEWS 8 MAY 30 The F-Term thesaurus is now available in CA/CAPLUS  
NEWS 9 JUN 02 The first reclassification of IPC codes now complete in  
INPADOC  
NEWS 10 JUN 26 TULSA/TULSA2 reloaded and enhanced with new search and  
and display fields  
NEWS 11 JUN 28 Price changes in full-text patent databases EPFULL and PCTFULL  
NEWS 12 JUL 11 CHEMSAFE reloaded and enhanced  
NEWS 13 JUL 14 FSTA enhanced with Japanese patents  
NEWS 14 JUL 19 Coverage of Research Disclosure reinstated in DWPI  
NEWS 15 AUG 09 INSPEC enhanced with 1898-1968 archive  
NEWS 16 AUG 28 ADISCTI Reloaded and Enhanced  
NEWS 17 AUG 30 CA(SM)/CAPLUS(SM) Austrian patent law changes  
NEWS 18 SEP 11 CA/CAPLUS enhanced with more pre-1907 records

NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8  
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 15:06:58 ON 20 SEP 2006

=> file caplus  
COST IN U.S. DOLLARS  
FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FILE 'CAPLUS' ENTERED AT 15:07:09 ON 20 SEP 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Sep 2006 VOL 145 ISS 13  
FILE LAST UPDATED: 19 Sep 2006 (20060919/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s HAUSP and MDM2  
51 HAUSP  
2970 MDM2  
L1 21 HAUSP AND MDM2

=> s l1 not py>2004  
2147267 PY>2004  
L2 6 L1 NOT PY>2004

=> d ibib 1-6

L2 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2005:63694 CAPLUS  
DOCUMENT NUMBER: 143:224203  
TITLE: Dynamics in the p53-Mdm2 ubiquitination pathway  
AUTHOR(S): Brooks, Christopher L.; Gu, Wei  
CORPORATE SOURCE: Institute for Cancer Genetics and Department of Pathology; College of Physicians and Surgeons, Columbia University, New York, NY, USA  
SOURCE: Cell Cycle (2004), 3(7), 895-899  
CODEN: CCEYAS; ISSN: 1538-4101  
PUBLISHER: Landes Bioscience  
DOCUMENT TYPE: Journal; General Review  
LANGUAGE: English  
REFERENCE COUNT: 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2005:60430 CAPLUS  
DOCUMENT NUMBER: 142:215611  
TITLE: HAUSP is required for p53 destabilization  
AUTHOR(S): Cummins, Jordan M.; Vogelstein, Bert  
CORPORATE SOURCE: The Howard Hughes Medical Institute, The Sidney Kimmel Comprehensive Cancer Center, Program in Cellular and Molecular Medicine, The Johns Hopkins University Medical Institutions, Baltimore, MD, USA  
SOURCE: Cell Cycle (2004), 3(6), 689-692  
CODEN: CCEYAS; ISSN: 1538-4101  
PUBLISHER: Landes Bioscience  
DOCUMENT TYPE: Journal

LANGUAGE: English  
REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2004:900604 CAPLUS  
DOCUMENT NUMBER: 142:4278  
TITLE: HAUSP/USP7 as an Epstein-Barr virus target  
AUTHOR(S): Holowaty, M. N.; Frappier, L.  
CORPORATE SOURCE: Department of Medical Genetics and Microbiology,  
University of Toronto, Toronto, Can.  
SOURCE: Biochemical Society Transactions (2004), 32(5),  
731-732  
CODEN: BCSTB5; ISSN: 0300-5127  
PUBLISHER: Portland Press Ltd.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2004:398363 CAPLUS  
DOCUMENT NUMBER: 141:121361  
TITLE: P53 apoptotic pathway molecules are frequently and  
simultaneously altered in nonsmall cell lung carcinoma  
AUTHOR(S): Mori, Shoichi; Ito, Genshi; Usami, Noriyasu; Yoshioka,  
Hiromu; Ueda, Yuichi; Kodama, Yoshinori; Takahashi,  
Masahide; Fong, Kwun M.; Shimokata, Kaoru; Sekido,  
Yoshitaka  
CORPORATE SOURCE: Department of Clinical Preventive Medicine, Department  
of Thoracic Surgery, Nagoya University School of  
Medicine, Nagoya, Japan  
SOURCE: Cancer (New York, NY, United States) (2004), 100(8),  
1673-1682  
CODEN: CANCAR; ISSN: 0008-543X  
PUBLISHER: John Wiley & Sons, Inc.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2004:312009 CAPLUS  
DOCUMENT NUMBER: 140:300911  
TITLE: A dynamic role of HAUSP in the p53-  
Mdm2 pathway  
AUTHOR(S): Li, Muyang; Brooks, Christopher L.; Kon, Ning; Gu, Wei  
CORPORATE SOURCE: Institute for Cancer Genetics and Department of  
Pathology College of Physicians and Surgeons, Columbia  
University, New York, NY, 10032, USA  
SOURCE: Molecular Cell (2004), 13(6), 879-886  
CODEN: MOCEFL; ISSN: 1097-2765  
PUBLISHER: Cell Press  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2002:312567 CAPLUS  
DOCUMENT NUMBER: 137:44608  
TITLE: Deubiquitination of p53 by HAUSP is an  
important pathway for p53 stabilization  
AUTHOR(S): Li, Muyang; Chen, Delin; Shiloh, Ariel; Luo, Jianyuan;  
Nikolaev, Anatoly Y.; Qin, Jun; Gu, Wei

CORPORATE SOURCE: Institute for Cancer Genetics, and Department of  
Pathology, College of Physicians & Surgeons, Columbia  
University, New York, NY, 10032, USA  
SOURCE: Nature (London, United Kingdom) (2002), 416(6881),  
648-652  
CODEN: NATUAS; ISSN: 0028-0836  
PUBLISHER: Nature Publishing Group  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s usp7  
L3 40 USP7

=> s l3 and MDM2  
2970 MDM2  
L4 8 L3 AND MDM2

=> d ibib 1-8

L4 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2006:197641 CAPLUS  
DOCUMENT NUMBER: 144:288171  
TITLE: Molecular recognition of p53 and MDM2 by  
USP7/HAUSP  
AUTHOR(S): Sheng, Yi; Saridakis, Vivian; Sarkari, Feroz; Duan,  
Shili; Wu, Tianne; Arrowsmith, Cheryl H.; Frappier,  
Lori  
CORPORATE SOURCE: Department of Medical Biophysics, Ontario Cancer  
Institute, Toronto, ON, M5G 1L7, Can.  
SOURCE: Nature Structural & Molecular Biology (2006), 13(3),  
285-291  
CODEN: NSMBCU; ISSN: 1545-9993  
PUBLISHER: Nature Publishing Group  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2006:156572 CAPLUS  
DOCUMENT NUMBER: 145:119254  
TITLE: Structural basis of competitive recognition of p53 and  
MDM2 by HAUSP/USP7: implications for  
the regulation of the p53-MDM2 pathway  
AUTHOR(S): Hu, Min; Gu, Lichuan; Li, Muyang; Jeffrey, Philip D.;  
Gu, Wei; Shi, Yigong  
CORPORATE SOURCE: Department of Molecular Biology, Lewis Thomas  
Laboratory, Princeton University, Princeton, NJ, USA  
SOURCE: PLoS Biology (2006), 4(2), 228-239  
CODEN: PBLIBG; ISSN: 1545-7885  
URL: [http://biology.plosjournals.org/archive/1545-7885/4/2/pdf/10.1371\\_1545-7885\\_4\\_2\\_complete.pdf](http://biology.plosjournals.org/archive/1545-7885/4/2/pdf/10.1371_1545-7885_4_2_complete.pdf)  
PUBLISHER: Public Library of Science  
DOCUMENT TYPE: Journal; (online computer file)  
LANGUAGE: English  
REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2005:1056192 CAPLUS  
DOCUMENT NUMBER: 143:455700  
TITLE: Reciprocal activities between herpes simplex virus

type 1 regulatory protein ICP0, a ubiquitin E3 ligase,  
and ubiquitin-specific protease USP7  
AUTHOR(S): Boutell, Chris; Canning, Mary; Orr, Anne; Everett,  
Roger D.  
CORPORATE SOURCE: MRC Virology Unit, Institute of Virology, Glasgow, G11  
5JR, UK  
SOURCE: Journal of Virology (2005), 79(19), 12342-12354  
CODEN: JOVIAM; ISSN: 0022-538X  
PUBLISHER: American Society for Microbiology  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2005:327153 CAPLUS  
DOCUMENT NUMBER: 143:2872  
TITLE: Structure of the p53 binding domain of HAUSP/  
USP7 bound to Epstein-Barr nuclear antigen 1:  
Implications for EBV-mediated immortalization  
AUTHOR(S): Saridakis, Vivian; Sheng, Yi; Sarkari, Feroz;  
Holowaty, Melissa N.; Shire, Kathy; Nguyen, Tin;  
Zhang, Rongguang G.; Liao, Jack; Lee, Weontae;  
Edwards, Aled M.; Arrowsmith, Cheryl H.; Frappier,  
Lori  
CORPORATE SOURCE: Department of Medical Genetics and Microbiology,  
University of Toronto, Toronto, ON, M5S 1A8, Can.  
SOURCE: Molecular Cell (2005), 18(1), 25-36  
CODEN: MOCEFL; ISSN: 1097-2765  
PUBLISHER: Cell Press  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2005:60430 CAPLUS  
DOCUMENT NUMBER: 142:215611  
TITLE: HAUSP is required for p53 destabilization  
AUTHOR(S): Cummins, Jordan M.; Vogelstein, Bert  
CORPORATE SOURCE: The Howard Hughes Medical Institute, The Sidney Kimmel  
Comprehensive Cancer Center, Program in Cellular and  
Molecular Medicine, The Johns Hopkins University  
Medical Institutions, Baltimore, MD, USA  
SOURCE: Cell Cycle (2004), 3(6), 689-692  
CODEN: CCEYAS; ISSN: 1538-4101  
PUBLISHER: Landes Bioscience  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2005:1997 CAPLUS  
DOCUMENT NUMBER: 142:111841  
TITLE: Gene expression profiles and biomarkers for the  
detection of depression-related and other  
disease-related gene transcripts in blood  
INVENTOR(S): Liew, Choong-Chin  
PATENT ASSIGNEE(S): Chondrogene Limited, Can.  
SOURCE: U.S. Pat. Appl. Publ., 154 pp., Cont.-in-part of U.S.  
Ser. No. 802,875.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 31  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004265868	A1	20041230	US 2004-812702	20040330
US 2004014059	A1	20040122	US 2002-268730	20021009
US 2006134635	A1	20060622	US 2004-802875	20040312
US 2005191637	A1	20050901	US 2004-803737	20040318
US 2005196762	A1	20050908	US 2004-803759	20040318
US 2005196763	A1	20050908	US 2004-803857	20040318
US 2005196764	A1	20050908	US 2004-803858	20040318
US 2005208505	A1	20050922	US 2004-803648	20040318
PRIORITY APPLN. INFO.:			US 1999-115125P	P 19990106
			US 2000-477148	B1 20000104
			US 2002-268730	A2 20021009
			US 2003-601518	A2 20030620
			US 2004-802875	A2 20040312
			US 2001-271955P	P 20010228
			US 2001-275017P	P 20010312
			US 2001-305340P	P 20010713
			US 2002-85783	A2 20020228

L4 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2004:900604 CAPLUS  
DOCUMENT NUMBER: 142:4278  
TITLE: HAUSP/USP7 as an Epstein-Barr virus target  
AUTHOR(S): Holowaty, M. N.; Frappier, L.  
CORPORATE SOURCE: Department of Medical Genetics and Microbiology,  
University of Toronto, Toronto, Can.  
SOURCE: Biochemical Society Transactions (2004), 32(5),  
731-732  
CODEN: BCSTB5; ISSN: 0300-5127  
PUBLISHER: Portland Press Ltd.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2000:114335 CAPLUS  
DOCUMENT NUMBER: 132:332744  
TITLE: A genome-wide survey of RAS transformation targets  
AUTHOR(S): Zuber, Johannes; Tchernitsa, Oleg I.; Hinzmann, Bernd;  
Schmitz, Anne-Chantal; Grips, Martin; Hellriegel,  
Martin; Sers, Christine; Rosenthal, Andre; Schafer,  
Reinhold  
CORPORATE SOURCE: Laboratory of Molecular Tumour Pathology, Institute of  
Pathology, Charite, Humboldt-University, Berlin,  
D-10117, Germany  
SOURCE: Nature Genetics (2000), 24(2), 144-152  
CODEN: NGENEC; ISSN: 1061-4036  
PUBLISHER: Nature America  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file pctfull  
COST IN U.S. DOLLARS  
FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
30.31	30.52

FILE 'PCTFULL' ENTERED AT 15:12:56 ON 20 SEP 2006

COPYRIGHT (C) 2006 Univentio

FILE LAST UPDATED: 18 SEP 2006 <20060918/UP>  
MOST RECENT UPDATE WEEK: 200637 <200637/EW>  
FILE COVERS 1978 TO DATE

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

>>> NEW IPC8 DATA AND FUNCTIONALITY NOW AVAILABLE IN THIS FILE.

SEE

<http://www.stn-international.de/stndatabases/details/ipc-reform.html> >>>

>>> FOR CHANGES IN PCTFULL PLEASE SEE HELP CHANGE  
(last updated April 10, 2006) <<<

>>> NEW PRICES IN PCTFULL AS OF 01 JULY 2006. FOR DETAILS,  
PLEASE SEE HELP COST <<<

=> s USP7

L5 37 USP7

=> s HAUSP

L6 34 HAUSP

=> s 16 or 15

L7 59 L6 OR L5

=> s MDM2 and 17

829 MDM2

L8 18 MDM2 AND L7

=> s screen? or ident?

194428 SCREEN?

478664 IDENT?

L9 532010 SCREEN? OR IDENT?

=> s 19 and 18

L10 18 L9 AND L8

=> s 110 not py>2002

444636 PY>2002

L11 5 L10 NOT PY>2002

=> d ibib 1-5

L11 ANSWER 1 OF 5

ACCESSION NUMBER:

TITLE (ENGLISH):

TITLE (FRENCH):

INVENTOR(S):

PATENT ASSIGNEE(S):

AGENT:

LANGUAGE OF FILING:

LANGUAGE OF PUBL.:

DOCUMENT TYPE:

PATENT INFORMATION:

PCTFULL COPYRIGHT 2006 Univentio on STN

2002070742 PCTFULL ED 20020926 EW 200237

METHOD FOR THE DEVELOPMENT OF GENE PANELS FOR  
DIAGNOSTIC AND THERAPEUTIC PURPOSES BASED ON THE  
EXPRESSION AND METHYLATION STATUS OF THE GENES

PROCEDE DE MISE AU POINT DE GROUPES D'ECHANTILLONS DE  
GENES A DES FINS DE DIAGNOSTIC ET DE THERAPIE QUI SONT  
BASES SUR L'EXPRESSION ET L'ETAT DE METHYLATION DES  
GENES

OLEK, Alexander, Schroederstrasse 13/2, 10115 Berlin,  
DE;

BERLIN, Kurt, Marienkaeferweg 4, 14532 Stahndorf, DE

EPIGENOMICS AG, Kastanienalle 24, 10435 Berlin, DE [DE,  
DE]

SCHOHE, Stefan\$, Boehmert & Boehmert, Pettenkoferstr.  
20-22, 80336 Muenchen\$, DE

English

English

Patent

	NUMBER	KIND	DATE
	WO 2002070742	A1	20020912
DESIGNATED STATES			
W:	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW		
RW (ARIPO):	GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW		
RW (EAPO):	AM AZ BY KG KZ MD RU TJ TM		
RW (EPO):	AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR		
RW (OAPI):	BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2002-EP2255	A	20020301
PRIORITY INFO.:	US 2001-60/272,549		20010301
L11 ANSWER 2 OF 5	PCTFULL COPYRIGHT 2006 Univentio on STN		
ACCESSION NUMBER:	2002070741 PCTFULL ED 20020926 EW 200237		
TITLE (ENGLISH):	METHODS, SYSTEMS AND COMPUTER PROGRAM PRODUCTS FOR DETERMINING THE BIOLOGICAL EFFECT AND/OR ACTIVITY OF DRUGS, CHEMICAL SUBSTANCES AND/OR PHARMACEUTICAL COMPOSITIONS BASED ON THEIR EFFECT ON THE METHYLATION STATUS OF THE DNA		
TITLE (FRENCH):	PROCEDES, SYSTEMES ET PRODUITS PROGRAMMES INFORMATIQUES PERMETTANT DE DETERMINER L'EFFET BIOLOGIQUE ET/OU L'ACTIVITE DE MEDICAMENTS, DE SUBSTANCES CHIMIQUES ET/OU DE COMPOSITIONS PHARMACEUTIQUES, SUR LA BASE DE LEUR EFFET SUR L'ETAT DE METHYLATION DE L'ADN		
INVENTOR(S):	OLEK, Alexander, Schroederstrasse 13/2, 10115 Berlin, DE;		
PATENT ASSIGNEE(S):	BERLIN, Kurt, Marienkaeferweg 4, 14532 Stahnsdorf, DE EPIGENOMICS AG, Kastanienallee 24, 10435 Berlin, DE [DE, DE]		
AGENT:	SCHOHE, Stefan\$, Boehmert & Boehmert, Pettenkoferstrasse 20-22, 80336 Muenchen\$, DE		
LANGUAGE OF FILING:	English		
LANGUAGE OF PUBL.:	English		
DOCUMENT TYPE:	Patent		
PATENT INFORMATION:			
	NUMBER	KIND	DATE
	WO 2002070741	A2	20020912
DESIGNATED STATES			
W:	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW		
RW (ARIPO):	GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW		
RW (EAPO):	AM AZ BY KG KZ MD RU TJ TM		
RW (EPO):	AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR		
RW (OAPI):	BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2002-EP2254	A	20020301
PRIORITY INFO.:	US 2001-60/272,484		20010301
L11 ANSWER 3 OF 5	PCTFULL COPYRIGHT 2006 Univentio on STN		
ACCESSION NUMBER:	2002057414 PCTFULL ED 20020801 EW 200230		
TITLE (ENGLISH):	LEUKOCYTE EXPRESSION PROFILING		
TITLE (FRENCH):	EVALUATION DU NIVEAU D'EXPRESSION LEUCOCYTAIRE		
INVENTOR(S):	WOHLGEMUTH, Jay, 664 Hamilton Avenue, Palo Alto, CA 94301, US [US, US]; FRY, Kirk, 2604 Ross Road, Palo Alto, CA 94303, US [US, US];		



PATENT ASSIGNEE(S):

MATCUK, George, 141C Escondido Village, Stanford, CA 94305, US [US, US];  
 ALTMAN, Peter, 717 Evelyn Avenue, Albany, CA 94706, US [US, US];  
 PRENTICE, James, 120 Dolores Street, San Francisco, CA 94103, US [US, US];  
 PHILLIPS, Julie, 1090 Mirador Terrace, Pacifica, CA 94044, US [US, US];  
 LY, Ngoc, 2000 Crystal Springs Road 15-14, San Bruno, CA 94066, US [US, US];  
 WOODWARD, Robert, 1828 Rheem Court, Pleasanton, CA 94588, US [US, US];  
 QUENTERMOUS, Thomas, 44 El Rey Road, Portola Valley, CA 94028, US [US, US];  
 JOHNSON, Frances, 44 El Rey Road, Portola Valley, CA 94028, US [US, US];  
 BIOCARDIA, INC., 384 Oyster Point Boulevard, #4, South San Francisco, CA 94080, US [US, US], for all designates States except US;  
 WOHLGEMUTH, Jay, 664 Hamilton Avenue, Palo Alto, CA 94301, US [US, US], for US only;  
 FRY, Kirk, 2604 Ross Road, Palo Alto, CA 94303, US [US, US], for US only;  
 MATCUK, George, 141C Escondido Village, Stanford, CA 94305, US [US, US], for US only;  
 ALTMAN, Peter, 717 Evelyn Avenue, Albany, CA 94706, US [US, US], for US only;  
 PRENTICE, James, 120 Dolores Street, San Francisco, CA 94103, US [US, US], for US only;  
 PHILLIPS, Julie, 1090 Mirador Terrace, Pacifica, CA 94044, US [US, US], for US only;  
 LY, Ngoc, 2000 Crystal Springs Road 15-14, San Bruno, CA 94066, US [US, US], for US only;  
 WOODWARD, Robert, 1828 Rheem Court, Pleasanton, CA 94588, US [US, US], for US only;  
 QUENTERMOUS, Thomas, 44 El Rey Road, Portola Valley, CA 94028, US [US, US], for US only;  
 JOHNSON, Frances, 44 El Rey Road, Portola Valley, CA 94028, US [US, US], for US only;  
 AGENT: WARD, Michael, R.\$, Morrison & Foerster LLP, 425 Market Street, San Francisco, CA 94105-2482\$, US

LANGUAGE OF FILING: English  
 LANGUAGE OF PUBL.: English  
 DOCUMENT TYPE: Patent  
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2002057414	A2	20020725

DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR  
 CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID  
 IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD  
 MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK  
 SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZW  
 RW (EAPO): AM AZ BY KG KZ MD RU TJ TM  
 RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE  
 TR

RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2001-US47856 A 20011022  
 PRIORITY INFO.: US 2000-60/241,994 20001020  
 US 2001-60/296,764 20010608

TITLE (ENGLISH): TREATMENT OF CANCER  
 TITLE (FRENCH): TRAITEMENT ANTICANCEREUX  
 INVENTOR(S): NIZETIC, Dean;  
 GROET, JuergenRP : GILL JENNINGS & EVERY  
 PATENT ASSIGNEE(S): SCHOOL OF PHARMACY, UNIVERSITY OF LONDON;  
 NIZETIC, Dean;  
 GROET, Juergen  
 LANGUAGE OF PUBL.: English  
 DOCUMENT TYPE: Patent  
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2000079267	A2	20001228

# DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU  
 CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN  
 IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK  
 MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM  
 TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD  
 SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY  
 DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG  
 CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2000-GB2446 A 20000622  
 PRIORITY INFO.: GB 2000-0008161.2 20000403  
 GB 1999-9914589.8 19990622

L11 ANSWER 5 OF 5

ACCESSION NUMBER:

TITLE (ENGLISH):

TITLE (FRENCH):

INVENTOR(S):

PATENT ASSIGNEE(S):

PCTFULL COPYRIGHT 2006 Univentio on STN  
 2000073479 PCTFULL ED 20020515  
 A COMBINED GROWTH FACTOR-DELETED AND THYMIDINE  
 KINASE-DELETED VACCINIA VIRUS VECTOR  
 VECTEUR DU VIRUS DE LA VACCINE COMBINANT DELETION DU  
 FACTEUR DE CROISSANCE ET DELETION DE THYMIDINE KINASE  
 MCCART, J., Andrea;  
 BARTLETT, David, L.;  
 MOSS, BernardRP : NATAUPSKY, Steven, J.  
 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as  
 represented by THE SECRETARY, DEPARTMENT OF HEALTH AND  
 HUMAN SERVICES;  
 MCCART, J., Andrea;  
 BARTLETT, David, L.;  
 MOSS, Bernard

LANGUAGE OF PUBL.: English  
 DOCUMENT TYPE: Patent  
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2000073479	A1	20001207

# DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ  
 DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS  
 JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN  
 MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT  
 TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ  
 TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK  
 ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM  
 GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2000-US14679 A 20000526  
 PRIORITY INFO.: US 1999-60/137,126 19990528

=> d kwic 4

L11 ANSWER 4 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN

DETD . . . as p53, could perhaps explain the

link to deletions of USPs in solid tumours. De-ubiquitination could play a major role in the Mdm2 mediated control of p53 levels and its activation mechanism, since the ubiquitin-mediated proteasome degradation of p53 is an important effector arm of. . .

In recent years a number of other protein modifying polypeptide tags have been identified. Many of these are related to ubiquitin and have high levels of identity and similarity (determined using the BLAST algorithm, for instance) to ubiquitin itself. There is a recognised super family of such proteins which. . .

human SUMO-1 (PIC1 1 Sentrin, hSmt3C), SUMO-2 (hSmt3A) and SUMO-3 (hSMT3B) belong to the same family of UbL proteins with approximately 50% identity between themselves, and some 15-30% identity and 40-60% similarity in amino acid sequence to ubiquitin (Lapenta et al. 1997, Mannen et al. 1996, Kamitani et al. 1998, Saitoh. . .

Several UbL hydrolase enzymes have been identified which convert precursor UbL to active UbL. Some such enzymes interact with ubiquitin itself as well as with other UbL's. Proteases involved in cleavage of conjugates of UbL with target protein have been identified for instance SENP1 and SUSP-1, which were recently cloned (Kim et al. 2000, Gong et al. 2000a), and found to specifically cleave. . .

Valero, et al. (1999) published after the first priority date of the present application, have, in parallel identified this gene and pointed out the gene product's sequence homologies to known USIP's in the conserved peptide domains previously identified e.g. by d'Andrea et al (1998). They postulate a role in Alzheimer's disease. This protein has the HUGO approved name USP25.

fusion protein of the ubiquitin-like protein of interest and a detectable protein, and using the usual separation and immune based or autoradiographic identification techniques.

the specified domains, some level of sequence homology with sequence ID 1, for instance at least 20%, preferably at least 50%, identity with that sequence, and a level of similarity of at least 50%, preferably at least 70% or more with that sequence (in. . .

the corresponding mouse product, described in Valero, et al 1999 may be used or sequences which have the above levels of identity and similarity with such a sequence.

outside the specified domains, some level of sequence homology with sequence ID 1 for instance at least 20%, preferably at least 50%, identity with that sequence, and a level of similarity of at least 50%, preferably at least 70% or more with that sequence (in. . . as the corresponding mouse product, described in Valero, et al 1999 may be used or sequences which have the above levels of identity and similarity with such a sequence.

#### Experimental

We identify a portion of human chromosome 21 homozygously deleted in non-small cell non carcinoma (NSCLC) for further study. The region contained the DNA. . . et al. We found a shared region of overlap (SRO) for the hemizygous loss in other NSCLC. The current work is to identify genes in the SRO which have a potential role in tumour suppression.

The exposure was for 14 hr to Molecular Dynamics (Sunnyvale, CA) Phosphorimager screens. The I.M.A.G.E. Consortium (Lennon et al., 1996) cDNA clone ID 82471 0 and the Unigene clone A0021343 have been used as labelled. . .

#### Identification and cloning of USP26

Twelve sequenced exon-trapped products, when analysed using BLAST-N against public sequence databases, revealed clusters of overlapping cDNA clones. Sequences. . .

with the binding of USP25 to its natural ubiquitinated substrates, since this residue is conserved between all UCH-s and USP-s so far identified.

of the sequences found to be interacting, from the GenBank database are given in the table, Table 1. Summary of frequency and identities of specific interacting proteins from human brain with USP25-C178A, detected using Yeast-Two-Hybrid technique  
Summary of Results by Number of specific Accession number decreasing. . .

#### SUMO-

1 (PIC1, Sentrin, hSmt3C), SUMO-2 (hSmt3A) and SUMO-3 (hSMT3B) belong to the same family of UbL proteins with approximately 50% identity between themselves, and some 15-30% identity and 40-60% similarity in amino acid sequence to ubiquitin (Lapenta et al. 1997, Mannen et al. 1996, Kamitani et al. 1998, Saitoh. . .

#### Figure Legends

Figure 1. Identification of the Shared Region of Overlap (S.R.O.) for hemizygous deletions in 21q11-q21 in NSCLC Cytogenetic map, Not I long range physical. . .

the single key aminoacids in the Cys and His domains. Two reports show the localisations

of the highly homologous sequences for the HAUSP gene to 3p21  
(Kashuba,  
et al 1997) and 16p13 (Robinson, et al 1998), respectively.

A. 1992. Ubiquitin-specific  
proteases of *Saccharomyces cerevisiae*. J. Biol Chem 267:23364  
Baker, R.T., Wang, X-W., Woollatt, E., White, J.A. and Sutherlands,  
G.R. Identification, functional characterisation, and  
chromosomal  
localisation of USP15, a novel Human USP related to Unp Oncoprotein, and  
a systematic nomenclature for hUSP's. Genomics. . .

T., Saito, A... Suzuki, M., Shinomiya, H., Suzuki, T.,  
Takahashi, E., Tanigami, A., Ichiyama, A., Chung, C.H., Nakamura, Y.,  
and  
Tanaka, K. Identification and chromosomal assignment of USP1 ,  
a novel  
gene encoding a human ubiquitin-specific protease. Genomics, 54:155-158,  
1998.

human chromosome 5q33-q34, UBH1,  
encodes a novel deubiquitinating enzyme. Genomics 49:411  
Haupt Y, Maya R, Kazaz A, Oren M (1997) Mdm2 promotes the  
rapid  
degradation of p53, Nature 387:296  
Ichikawa, H., Hosoda, F., Arai, Y., Shimizu, K., Ohira, M., and Ohki,  
M. A. . .

Sumegi J, Klein G,  
Zabarovsky ER, Kisselev L. 1997. Not1 linking/jumping clones of human  
chromosome 3: mapping of the TFRC, RA137 and HAUSP genes to  
regions  
rearranged in leukemia and deleted in solid tumours. FEBS Lett 419:181-  
185.

Assignment of herpesvirus-associated ubiquitin-specific protease gene  
HAUSP to human chromosome band 16p13.3 by in situ  
hybridisation,  
Cytogenet. Cell Genet. 83:100.

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

15.52

46.04

FILE 'REGISTRY' ENTERED AT 15:17:14 ON 20 SEP 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 19 SEP 2006 HIGHEST RN 907944-91-6

DICTIONARY FILE UPDATES: 19 SEP 2006 HIGHEST RN 907944-91-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

Effective September 24, 2006, Concord 3D coordinates will no longer  
be available. Please contact CAS Customer Care  
(<http://www.cas.org/supp.html>) if you have a need for 3D coordinates.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> E "HAUSP"/CN 25

E1	1	HAUSMANNITE, MAGNESIAN (MN2(MN0.5-0.9MG0.1-0.5)O4)/CN
E2	1	HAUSMANNITE, ZINCIAN (MN2(MN0.5-0.9ZN0.1-0.5)O4)/CN
E3	0 -->	HAUSP/CN
E4	1	HAUSP PROTEASE/CN
E5	1	HAUSTELLUM SPECIFIC PROTEIN B (SARCOPHAGA PEREGRINA GENE HSPB)/CN
E6	1	HAUTHANE HD 2334/CN
E7	1	HAUTHANE HD 2334, POLYMER WITH MONDUR TD 80 AND POLY-G 83-34/CN
E8	1	HAUTHANE HD 2001/CN
E9	1	HAUTHANE HD 4664/CN
E10	1	HAUTHANE L 2020/CN
E11	1	HAUTHAWAY IDA/CN
E12	1	HAUTOFOAM ES-AL/CN
E13	1	HAUTOFOAM ES-SI/CN
E14	1	HAUTOFOAM ES-TI/CN
E15	1	HAUTOFOAM ITO/CN
E16	1	HAUTOFOAM MS-Y/CN
E17	1	HAUTOFOAM NI/CN
E18	1	HAUTOFOAM SN/CN
E19	1	HAUTRIWAIC ACID/CN
E20	1	HAUTRIWAIC ACID $\Gamma$ -LACTONE/CN
E21	1	HAUTRIWAIC ACID ACETATE/CN
E22	1	HAUTRIWAIC ACID LACTONE/CN
E23	1	HAUTRIWAIC ACID METHYL ESTER/CN
E24	1	HAUTRIWAIC ACID METHYL ESTER ACETATE/CN
E25	2	HAUYNE/CN

=> S E4

L12 1 "HAUSP PROTEASE"/CN

=> DIS L12 1 SQIDE

THE ESTIMATED COST FOR THIS REQUEST IS 6.36 U.S. DOLLARS  
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L12 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN

RN 109136-49-4 REGISTRY

CN Proteinase, ubiquitin conjugate (9CI) (CA INDEX NAME)

OTHER NAMES:

CN	DEN1 protease
CN	Deneddylase
CN	Deubiquitination enzyme UBP1
CN	Deubiquitinase
CN	Deubiquitinating enzyme
CN	Deubiquitinating enzyme DUB-2
CN	HAUSP protease
CN	ISG15-specific protease UBP43
CN	Otubain 1
CN	Polyubiquitin proteinase
CN	Protease USP21
CN	Proteinase, ubiquitin-fusion protein
CN	Ubiquitin conjugate protease
CN	Ubiquitin conjugate proteinase
CN	Ubiquitin protease
CN	Ubiquitin proteinase
CN	Ubiquitin-fusion protein proteinase

CN Ubiquitin-specific processing protease  
 CN Ubiquitin-specific protease  
 CN Ubiquitin-specific protease 21  
 CN Ubiquitin-specific proteinase  
 CN UBP1 protease  
 DR 123175-78-0, 123175-79-1  
 MF Unspecified  
 CI MAN  
 SR CA  
 LC STN Files: AGRICOLA, BIOSIS, CA, CAPLUS, CIN, PROMT, TOXCENTER, USPAT2,  
 USPATFULL  
 DT.CA Caplus document type: Conference; Dissertation; Journal; Patent  
 RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study);  
 MSC (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC  
 (Process); PRP (Properties); USES (Uses)  
 RLD.P Roles for non-specific derivatives from patents: ANST (Analytical  
 study); BIOL (Biological study); PREP (Preparation); PRP (Properties);  
 USES (Uses)  
 RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological  
 study); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP  
 (Properties); USES (Uses)  
 RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological  
 study); PROC (Process); PRP (Properties)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

610 REFERENCES IN FILE CA (1907 TO DATE)

7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

617 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> E "USP7"/CN 25

E1 1 USP6NL PROTEIN (HUMAN CLONE IMAGE:4838780)/CN  
 E2 1 USP6NL PROTEIN (HUMAN CLONE MGC:41831 IMAGE:5296060)/CN  
 E3 0 --> USP7/CN  
 E4 1 USP8 PROTEIN (HUMAN CLONE IMAGE:6429817 GENE USP8)/CN  
 E5 1 USP8 PROTEIN (MOUSE STRAIN FVB/N CLONE IMAGE:5041516 GENE  
 USP8)/CN  
 E6 1 USP8-PROV PROTEIN (XENOPUS LAEVIS CLONE MGC:53905  
 IMAGE:5543601)/CN  
 E7 1 USP9X PROTEIN (HUMAN CLONE IMAGE:4538919 GENE USP9X)/CN  
 E8 1 USP9X PROTEIN (HUMAN CLONE IMAGE:6175281 GENE USP9X)/CN  
 E9 1 USPA (MYCOBACTERIUM AVIUM PARATUBERCULOSIS STRAIN K-10 GENE  
 USPA)/CN  
 E10 1 USPA (NITROBACTER WINOGRADSKYI STRAIN NB-255)/CN  
 E11 1 USPA (PASTEURELLA MULTOCIDA STRAIN IL1403 CLONE PM70 GENE  
 USPA)/CN  
 E12 3 USPA (PSEUDOMONAS SYRINGAE SYRINGAE STRAIN B728A)/CN  
 E13 1 USPA FAMILY PROTEIN (BURKHOLDERIA MALLEI STRAIN ATCC 23344)/CN  
 E14 1 USPA FAMILY PROTEIN (BURKHOLDERIA THAILANDENSIS STRAIN E264)/CN  
 E15 3 USPA PROTEIN (MANNHEIMIA SUCCINICIPRODUCENS STRAIN MBEL55E GENE  
 USPA)/CN  
 E16 1 USPA-RELATED NUCLEOTIDE-BINDING PROTEIN (IDIOMARINA LOIHIENSIS  
 STRAIN L2TR GENE USPA)/CN  
 E17 1 USPA-RELATED NUCLEOTIDE-BINDING PROTEIN (IDIOMARINA LOIHIENSIS  
 STRAIN L2TR)/CN  
 E18 1 USPALLATINE/CN  
 E19 1 USPALLATINE 6-ACETATE/CN  
 E20 1 USPALLATINE ACETATE/CN  
 E21 1 USPALLATINECINE/CN  
 E22 1 USPC (MYCOBACTERIUM AVIUM PARATUBERCULOSIS STRAIN K-10 GENE  
 USPC)/CN  
 E23 1 USPCA/CN  
 E24 1 USPE (MYCOBACTERIUM AVIUM PARATUBERCULOSIS STRAIN K-10 GENE  
 USPE)/CN  
 E25 1 USPIO/CN

=> E "USP 7"/CN 25

E1	1	USP 400/CN
E2	1	USP 400P/CN
E3	0 -->	USP 7/CN
E4	1	USP 711/CN
E5	1	USP 90MD/CN
E6	1	USP DOMAIN (BACILLUS LICHENIFORMIS STRAIN ATCC 14580 GENE YXIE)/CN
E7	1	USP10-PROV PROTEIN (XENOPUS LAEVIS CLONE MGC:53812 IMAGE:5542105)/CN
E8	1	USP10-PROV PROTEIN (XENOPUS TROPICALIS CLONE MGC:89480 IMAGE:6991947 GENE USP10-PROV)/CN
E9	1	USP11 PROTEIN (HUMAN CLONE IMAGE:2961383 GENE USP11)/CN
E10	1	USP11 PROTEIN (HUMAN CLONE IMAGE:4180680 GENE USP11)/CN
E11	1	USP12 PROTEIN (MOUSE CLONE MGC:55011 IMAGE:4500832)/CN
E12	1	USP12 PROTEIN (MOUSE STRAIN FVB/N CLONE IMAGE:5100708 GENE USP12)/CN
E13	1	USP14 PROTEIN (MOUSE STRAIN 129/SV X 129/SV-CP CLONE MGC:60479 IMAGE:30006882)/CN
E14	1	USP15 PROTEIN (HUMAN CLONE IMAGE:4689787 GENE USP15)/CN
E15	1	USP15 PROTEIN (HUMAN CLONE IMAGE:4689787)/CN
E16	1	USP16 PROTEIN (MOUSE STRAIN CZECH II CLONE IMAGE:3586657 GENE USP16)/CN
E17	1	USP16 PROTEIN (XENOPUS TROPICALIS CLONE IMAGE:6990711 GENE USP16)/CN
E18	1	USP19 PROTEIN (HUMAN CLONE IMAGE:4478169 GENE USP19)/CN
E19	1	USP19 PROTEIN (HUMAN CLONE IMAGE:4859467 GENE USP19)/CN
E20	1	USP2 PROTEIN (HUMAN CLONE MGC:43844 IMAGE:5273400 GENE USP2)/CN
E21	1	USP2 PROTEIN (HUMAN CLONE MGC:43844 IMAGE:5273400)/CN
E22	1	USP2 PROTEIN (MOUSE CLONE MGC:27630 IMAGE:4506362)/CN
E23	1	USP21 PROTEIN (HUMAN CLONE IMAGE:2958151 GENE USP21)/CN
E24	1	USP21 PROTEIN (HUMAN CLONE MGC:3394 IMAGE:2958151)/CN
E25	1	USP22 PROTEIN (MOUSE STRAIN C57BL/6 CLONE IMAGE:5686812 GENE USP22)/CN

=> E "USP-7"/CN 25

E1	1	USP 90MD/CN
E2	1	USP DOMAIN (BACILLUS LICHENIFORMIS STRAIN ATCC 14580 GENE YXIE)/CN
E3	0 -->	USP-7/CN
E4	1	USP10-PROV PROTEIN (XENOPUS LAEVIS CLONE MGC:53812 IMAGE:5542105)/CN
E5	1	USP10-PROV PROTEIN (XENOPUS TROPICALIS CLONE MGC:89480 IMAGE:6991947 GENE USP10-PROV)/CN
E6	1	USP11 PROTEIN (HUMAN CLONE IMAGE:2961383 GENE USP11)/CN
E7	1	USP11 PROTEIN (HUMAN CLONE IMAGE:4180680 GENE USP11)/CN
E8	1	USP12 PROTEIN (MOUSE CLONE MGC:55011 IMAGE:4500832)/CN
E9	1	USP12 PROTEIN (MOUSE STRAIN FVB/N CLONE IMAGE:5100708 GENE USP12)/CN
E10	1	USP14 PROTEIN (MOUSE STRAIN 129/SV X 129/SV-CP CLONE MGC:60479 IMAGE:30006882)/CN
E11	1	USP15 PROTEIN (HUMAN CLONE IMAGE:4689787 GENE USP15)/CN
E12	1	USP15 PROTEIN (HUMAN CLONE IMAGE:4689787)/CN
E13	1	USP16 PROTEIN (MOUSE STRAIN CZECH II CLONE IMAGE:3586657 GENE USP16)/CN
E14	1	USP16 PROTEIN (XENOPUS TROPICALIS CLONE IMAGE:6990711 GENE USP16)/CN
E15	1	USP19 PROTEIN (HUMAN CLONE IMAGE:4478169 GENE USP19)/CN
E16	1	USP19 PROTEIN (HUMAN CLONE IMAGE:4859467 GENE USP19)/CN
E17	1	USP2 PROTEIN (HUMAN CLONE MGC:43844 IMAGE:5273400 GENE USP2)/CN
E18	1	USP2 PROTEIN (HUMAN CLONE MGC:43844 IMAGE:5273400)/CN
E19	1	USP2 PROTEIN (MOUSE CLONE MGC:27630 IMAGE:4506362)/CN
E20	1	USP21 PROTEIN (HUMAN CLONE IMAGE:2958151 GENE USP21)/CN
E21	1	USP21 PROTEIN (HUMAN CLONE MGC:3394 IMAGE:2958151)/CN



E22 1 USP22 PROTEIN (MOUSE STRAIN C57BL/6 CLONE IMAGE:5686812 GENE  
USP22)/CN  
E23 1 USP24 PROTEIN (HUMAN CLONE IMAGE:4995223 GENE USP24)/CN  
E24 1 USP24 PROTEIN (HUMAN CLONE MGC:29848 IMAGE:4995223)/CN  
E25 1 USP24 PROTEIN (MOUSE STRAIN C57BL/6J CLONE MGC:41753  
IMAGE:1381175)/CN  
=> E 25  
E26 1 USP25 PROTEIN (HUMAN CLONE IMAGE:3920963)/CN  
E27 1 USP25-PROV PROTEIN (XENOPUS LAEVIS CLONE MGC:81666 IMAGE:6864548  
GENE USP25-PROV)/CN  
E28 1 USP28 PROTEIN (HUMAN CLONE MGC:70638 IMAGE:6140725)/CN  
E29 1 USP28 PROTEIN (MOUSE STRAIN C57BL/6 CLONE MGC:91310  
IMAGE:6835629)/CN  
E30 1 USP3-PROV PROTEIN (XENOPUS TROPICALIS CLONE MGC:89592  
IMAGE:6994758 GENE USP3-PROV)/CN  
E31 1 USP30 PROTEIN (HUMAN CLONE IMAGE:3536512 GENE USP30)/CN  
E32 1 USP30 PROTEIN (MOUSE STRAIN FVB/N CLONE IMAGE:4911968 GENE  
USP30)/CN  
E33 1 USP31 PROTEIN (HUMAN CLONE IMAGE:4650466)/CN  
E34 1 USP32 PROTEIN (HUMAN CLONE IMAGE:6164242 GENE USP32)/CN  
E35 1 USP32 PROTEIN (HUMAN CLONE IMAGE:6502630)/CN  
E36 1 USP32 PROTEIN (MOUSE CLONE IMAGE:5369173 GENE USP32)/CN  
E37 1 USP32 PROTEIN (MOUSE STRAIN C57BL/6 CLONE IMAGE:5706776 GENE  
USP32)/CN  
E38 1 USP33 PROTEIN (MOUSE CLONE IMAGE:5359218 GENE USP33)/CN  
E39 1 USP33 PROTEIN (MOUSE STRAIN CZECH II CLONE IMAGE:5066137 GENE  
USP33)/CN  
E40 1 USP33 PROTEIN (MOUSE STRAIN MIX FVB/N, C57BL/6J CLONE  
IMAGE:3491447 GENE USP33)/CN  
E41 1 USP34 PROTEIN (HUMAN CLONE IMAGE:3846921 GENE USP34)/CN  
E42 1 USP34 PROTEIN (HUMAN CLONE IMAGE:5426830)/CN  
E43 1 USP34 PROTEIN (MOUSE STRAIN C57BL/6 CLONE IMAGE:5708348 GENE  
USP34)/CN  
E44 1 USP34 PROTEIN (MOUSE STRAIN CZECH II CLONE IMAGE:3983228 GENE  
USP34)/CN  
E45 1 USP36 PROTEIN (HUMAN CLONE MGC:87250 IMAGE:30345255)/CN  
E46 1 USP39 PROTEIN (HUMAN CLONE IMAGE:3050936 GENE USP39)/CN  
E47 1 USP4 PROTEIN (MOUSE STRAIN C57BL/6J CLONE IMAGE:30433369 GENE  
USP4)/CN  
E48 1 USP4 PROTEIN (MOUSE STRAIN C57BL/6J CLONE IMAGE:30457732 GENE  
USP4)/CN  
E49 1 USP4 PROTEIN (MOUSE STRAIN CZECH II CLONE MGC:18374  
IMAGE:3661165)/CN  
E50 1 USP42 PROTEIN (HUMAN CLONE IMAGE:30343487 GENE USP42)/CN  
=> E 25  
E51 1 USP43 PROTEIN (MOUSE STRAIN FVB/N CLONE IMAGE:3711168 GENE  
USP43)/CN  
E52 1 USP43 PROTEIN (MOUSE STRAIN FVB/N CLONE MGC:38313  
IMAGE:5343429)/CN  
E53 1 USP44 PROTEIN (HUMAN CLONE MGC:26981 IMAGE:4825887)/CN  
E54 1 USP45 PROTEIN (HUMAN CLONE MGC:14793 IMAGE:4047601)/CN  
E55 1 USP46-PROV PROTEIN (XENOPUS LAEVIS CLONE MGC:53480  
IMAGE:5572291)/CN  
E56 1 USP47 PROTEIN (HUMAN CLONE IMAGE:3350895 GENE USP47)/CN  
E57 1 USP47 PROTEIN (HUMAN CLONE IMAGE:5575723)/CN  
E58 1 USP47 PROTEIN (MOUSE STRAIN C57BL/6 CLONE IMAGE:6813792)/CN  
E59 1 USP47 PROTEIN (MOUSE STRAIN CZECH II CLONE IMAGE:5068518 GENE  
USP47)/CN  
E60 1 USP47 PROTEIN (MOUSE STRAIN FVB/N CLONE IMAGE:4211195 GENE  
USP47)/CN  
E61 1 USP48 PROTEIN (HUMAN CLONE IMAGE:3897418 GENE USP48)/CN  
E62 1 USP48 PROTEIN (HUMAN CLONE IMAGE:4650466 GENE USP48)/CN  
E63 1 USP48 PROTEIN (HUMAN CLONE IMAGE:4650466)/CN

E64 1 USP48 PROTEIN (HUMAN CLONE IMAGE:6514749 GENE USP48)/CN  
 E65 1 USP48 PROTEIN (MOUSE STRAIN FVB/N CLONE MGC:25724 IMAGE:3979404  
 GENE USP48)/CN  
 E66 1 USP49 PROTEIN (MOUSE STRAIN C57BL/6 CLONE MGC:63299  
 IMAGE:6408678)/CN  
 E67 1 USP5 PROTEIN (HUMAN CLONE MGC:1586 IMAGE:3506801)/CN  
 E68 1 USP51 PROTEIN (HUMAN CLONE IMAGE:5391875 GENE USP51)/CN  
 E69 1 USP52 PROTEIN (MOUSE STRAIN CZECH II CLONE IMAGE:3591885 GENE  
 USP52)/CN  
 E70 1 USP52 PROTEIN (MOUSE STRAIN FVB/N CLONE IMAGE:4988880)/CN  
 E71 1 USP53 PROTEIN (HUMAN CLONE MGC:22206 IMAGE:4082351)/CN  
 E72 1 USP53 PROTEIN (MOUSE STRAIN FVB/N CLONE IMAGE:4236151 GENE  
 USP53)/CN  
 E73 1 USP54 PROTEIN (HUMAN CLONE IMAGE:6148876 GENE USP54)/CN  
 E74 1 USP54 PROTEIN (MOUSE STRAIN CD1 CLONE IMAGE:30088889 GENE  
 USP54)/CN  
 E75 1 USP54 PROTEIN (MOUSE STRAIN CD1 CLONE IMAGE:30096132 GENE  
 USP54)/CN  
  
 => E 25  
 E76 1 USP6 N-TERMINAL LIKE (MOUSE CLONE MGC:57018 IMAGE:6466270 GENE  
 USP6NL)/CN  
 E77 1 USP6NL PROTEIN (HUMAN CLONE IMAGE:4047207 GENE USP6NL)/CN  
 E78 1 USP6NL PROTEIN (HUMAN CLONE IMAGE:4838780)/CN  
 E79 1 USP6NL PROTEIN (HUMAN CLONE MGC:41831 IMAGE:5296060)/CN  
 E80 1 USP8 PROTEIN (HUMAN CLONE IMAGE:6429817 GENE USP8)/CN  
 E81 1 USP8 PROTEIN (MOUSE STRAIN FVB/N CLONE IMAGE:5041516 GENE  
 USP8)/CN  
 E82 1 USP8-PROV PROTEIN (XENOPUS LAEVIS CLONE MGC:53905  
 IMAGE:5543601)/CN  
 E83 1 USP9X PROTEIN (HUMAN CLONE IMAGE:4538919 GENE USP9X)/CN  
 E84 1 USP9X PROTEIN (HUMAN CLONE IMAGE:6175281 GENE USP9X)/CN  
 E85 1 USPA (MYCOBACTERIUM AVIUM PARATUBERCULOSIS STRAIN K-10 GENE  
 USPA)/CN  
 E86 1 USPA (NITROBACTER WINOGRADSKYI STRAIN NB-255)/CN  
 E87 1 USPA (PASTEURELLA MULTOCIDA STRAIN IL1403 CLONE PM70 GENE  
 USPA)/CN  
 E88 3 USPA (PSEUDOMONAS SYRINGAE SYRINGAE STRAIN B728A)/CN  
 E89 1 USPA FAMILY PROTEIN (BURKHOLDERIA MALLEI STRAIN ATCC 23344)/CN  
 E90 1 USPA FAMILY PROTEIN (BURKHOLDERIA THAILANDENSIS STRAIN E264)/CN  
 E91 3 USPA PROTEIN (MANNHEIMIA SUCCINICIPRODUCENS STRAIN MBEL55E GENE  
 USPA)/CN  
 E92 1 USPA-RELATED NUCLEOTIDE-BINDING PROTEIN (IDIOMARINA LOIHIENSIS  
 STRAIN L2TR GENE USPA)/CN  
 E93 1 USPA-RELATED NUCLEOTIDE-BINDING PROTEIN (IDIOMARINA LOIHIENSIS  
 STRAIN L2TR)/CN  
 E94 1 USPALLATINE/CN  
 E95 1 USPALLATINE 6-ACETATE/CN  
 E96 1 USPALLATINE ACETATE/CN  
 E97 1 USPALLATINECINE/CN  
 E98 1 USPC (MYCOBACTERIUM AVIUM PARATUBERCULOSIS STRAIN K-10 GENE  
 USPC)/CN  
 E99 1 USPCA/CN  
 E100 1 USPE (MYCOBACTERIUM AVIUM PARATUBERCULOSIS STRAIN K-10 GENE  
 USPE)/CN

=> file medline

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

8.42

54.46

FILE 'MEDLINE' ENTERED AT 15:19:32 ON 20 SEP 2006

FILE LAST UPDATED: 19 Sep 2006 (20060919/UP). FILE COVERS 1950 TO DATE.

On December 11, 2005, the 2006 MeSH terms were loaded.

The MEDLINE reload for 2006 is now (26 Feb.) available. For details on the 2006 reload, enter HELP RLOAD at an arrow prompt (=>).  
See also:

<http://www.nlm.nih.gov/mesh/>  
[http://www.nlm.nih.gov/pubs/techbull/nd04/nd04\\_mesh.html](http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html)  
[http://www.nlm.nih.gov/pubs/techbull/nd05/nd05\\_med\\_data\\_changes.html](http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_med_data_changes.html)  
[http://www.nlm.nih.gov/pubs/techbull/nd05/nd05\\_2006\\_MeSH.html](http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_2006_MeSH.html)

OLDMEDLINE is covered back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2006 vocabulary.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s HAUSP or (USP () 7)
      39 HAUSP
      4983 USP
      37 USPS
      5006 USP
      (USP OR USPS)
      1527014 7
      0 USP (W) 7
L13      39 HAUSP OR (USP (W) 7)
```

```
=> s HAUSP or (USP7)
      39 HAUSP
      47 USP7
L14      55 HAUSP OR (USP7)
```

```
=> s MDM2
L15      2699 MDM2
```

```
=> s l15 and l14
L16      18 L15 AND L14
```

```
=> s l16 not py>2002
      2271354 PY>2002
      (PY>20029999)
L17      1 L16 NOT PY>2002
```

```
=> d ibib
```

```
L17 ANSWER 1 OF 1      MEDLINE on STN
ACCESSION NUMBER:      2002212418      MEDLINE
DOCUMENT NUMBER:      PubMed ID: 11923872
TITLE:      Deubiquitination of p53 by HAUSP is an important
              pathway for p53 stabilization.
AUTHOR:      Li Muyang; Chen Delin; Shiloh Ariel; Luo Jianyuan; Nikolaev
              Anatoly Y; Qin Jun; Gu Wei
CORPORATE SOURCE:      Institute for Cancer Genetics; and Department of Pathology,
              College of Physicians & Surgeons, Columbia University, 1150
              St Nicholas Avenue, New York, New York 10032, USA.
SOURCE:      Nature, (2002 Apr 11) Vol. 416, No. 6881, pp. 648-53.
              Electronic Publication: 2002-03-31.
              Journal code: 0410462. ISSN: 0028-0836.
PUB. COUNTRY:      England: United Kingdom
DOCUMENT TYPE:      Journal; Article; (JOURNAL ARTICLE)
LANGUAGE:      English
FILE SEGMENT:      Priority Journals
ENTRY MONTH:      200205
```

ENTRY DATE: Entered STN: 12 Apr 2002  
Last Updated on STN: 18 May 2002  
Entered Medline: 17 May 2002

=> d abs

L17 ANSWER 1 OF 1 MEDLINE on STN  
AB The p53 tumour suppressor is a short-lived protein that is maintained at low levels in normal cells by Mdm2-mediated ubiquitination and subsequent proteolysis. Stabilization of p53 is crucial for its tumour suppressor function. However, the precise mechanism by which ubiquitinated p53 levels are regulated in vivo is not completely understood. By mass spectrometry of affinity-purified p53-associated factors, we have identified herpesvirus-associated ubiquitin-specific protease (HAUSP) as a novel p53-interacting protein. HAUSP strongly stabilizes p53 even in the presence of excess Mdm2, and also induces p53-dependent cell growth repression and apoptosis. Significantly, HAUSP has an intrinsic enzymatic activity that specifically deubiquitinates p53 both in vitro and in vivo. In contrast, expression of a catalytically inactive point mutant of HAUSP in cells increases the levels of p53 ubiquitination and destabilizes p53. These findings reveal an important mechanism by which p53 can be stabilized by direct deubiquitination and also imply that HAUSP might function as a tumour suppressor in vivo through the stabilization of p53.

=> d his

(FILE 'HOME' ENTERED AT 15:06:58 ON 20 SEP 2006)

FILE 'CAPLUS' ENTERED AT 15:07:09 ON 20 SEP 2006

L1 21 S HAUSP AND MDM2  
L2 6 S L1 NOT PY>2004  
L3 40 S USP7  
L4 8 S L3 AND MDM2

FILE 'PCTFULL' ENTERED AT 15:12:56 ON 20 SEP 2006

L5 37 S USP7  
L6 34 S HAUSP  
L7 59 S L6 OR L5  
L8 18 S MDM2 AND L7  
L9 532010 S SCREEN? OR IDENT?  
L10 18 S L9 AND L8  
L11 5 S L10 NOT PY>2002

FILE 'REGISTRY' ENTERED AT 15:17:14 ON 20 SEP 2006

L12 1 S E4  
E "HAUSP"/CN 25  
E "USP7"/CN 25  
E "USP 7"/CN 25  
E "USP-7"/CN 25

FILE 'MEDLINE' ENTERED AT 15:19:32 ON 20 SEP 2006

L13 39 S HAUSP OR (USP ( ) 7)  
L14 55 S HAUSP OR (USP7)  
L15 2699 S MDM2  
L16 18 S L15 AND L14  
L17 1 S L16 NOT PY>2002

=> file pctfull

COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE  
ENTRY  
3.73

TOTAL  
SESSION  
58.19

FILE 'PCTFULL' ENTERED AT 15:24:49 ON 20 SEP 2006  
COPYRIGHT (C) 2006 Univentio

FILE LAST UPDATED: 18 SEP 2006 <20060918/UP>  
MOST RECENT UPDATE WEEK: 200637 <200637/EW>  
FILE COVERS 1978 TO DATE

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

>>> NEW IPC8 DATA AND FUNCTIONALITY NOW AVAILABLE IN THIS FILE.

SEE

<http://www.stn-international.de/stndatabases/details/ipc-reform.html> >>>

>>> FOR CHANGES IN PCTFULL PLEASE SEE HELP CHANGE  
(last updated April 10, 2006) <<<

>>> NEW PRICES IN PCTFULL AS OF 01 JULY 2006. FOR DETAILS,  
PLEASE SEE HELP COST <<<

=> d 111 ibib

L11 ANSWER 1 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN  
ACCESSION NUMBER: 2002070742 PCTFULL ED 20020926 EW 200237  
TITLE (ENGLISH): METHOD FOR THE DEVELOPMENT OF GENE PANELS FOR  
DIAGNOSTIC AND THERAPEUTIC PURPOSES BASED ON THE  
EXPRESSION AND METHYLATION STATUS OF THE GENES  
TITLE (FRENCH): PROCEDE DE MISE AU POINT DE GROUPE D'ECHANTILLONS DE  
GENES A DES FINS DE DIAGNOSTIC ET DE THERAPIE QUI SONT  
BASEES SUR L'EXPRESSION ET L'ETAT DE METHYLATION DES  
GENES  
INVENTOR(S): OLEK, Alexander, Schroederstrasse 13/2, 10115 Berlin,  
DE;  
PATENT ASSIGNEE(S): BERLIN, Kurt, Marienkaeferweg 4, 14532 Stahndorf, DE  
EPIGENOMICS AG, Kastanienallee 24, 10435 Berlin, DE [DE,  
DE]  
AGENT: SCHOHE, Stefan\$, Boehmert & Boehmert, Pettenkoferstr.  
20-22, 80336 Muenchen\$, DE  
LANGUAGE OF FILING: English  
LANGUAGE OF PUBL.: English  
DOCUMENT TYPE: Patent  
PATENT INFORMATION:

NUMBER	KIND	DATE
-----		
WO 2002070742	A1	20020912

DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR  
CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID  
IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD  
MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI  
SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

RW (ARIPO):

GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW

RW (EAPO):

AM AZ BY KG KZ MD RU TJ TM

RW (EPO):

AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE  
TR

RW (OAPI):

BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.:

WO 2002-EP2255 A 20020301

PRIORITY INFO.:

US 2001-60/272,549 20010301

=> d 111 ibib 1-5

L11 ANSWER 1 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN  
ACCESSION NUMBER: 2002070742 PCTFULL ED 20020926 EW 200237  
TITLE (ENGLISH): METHOD FOR THE DEVELOPMENT OF GENE PANELS FOR

TITLE (FRENCH): DIAGNOSTIC AND THERAPEUTIC PURPOSES BASED ON THE  
EXPRESSION AND METHYLATION STATUS OF THE GENES  
PROCEDE DE MISE AU POINT DE GROUPES D'ECHANTILLONS DE  
GENES A DES FINS DE DIAGNOSTIC ET DE THERAPIE QUI SONT  
BASES SUR L'EXPRESSION ET L'ETAT DE METHYLATION DES  
GENES

INVENTOR(S): OLEK, Alexander, Schroederstrasse 13/2, 10115 Berlin,  
DE;

PATENT ASSIGNEE(S): BERLIN, Kurt, Marienkaeferweg 4, 14532 Stahndorf, DE  
EPIGENOMICS AG, Kastanienallee 24, 10435 Berlin, DE [DE,  
DE]

AGENT: SCHOHE, Stefan\$, Boehmert & Boehmert, Pettenkoferstr.  
20-22, 80336 Muenchen\$, DE

LANGUAGE OF FILING: English

LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2002070742	A1	20020912

# DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR  
CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID  
IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD  
MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI  
SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW  
GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW  
AM AZ BY KG KZ MD RU TJ TM  
AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE  
TR

RW (ARIPO):

RW (EAPO):

RW (EPO):

RW (OAPI):

APPLICATION INFO.:

PRIORITY INFO.:

BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG  
WO 2002-EP2255 A 20020301  
US 2001-60/272,549 20010301

L11 ANSWER 2 OF 5

ACCESSION NUMBER:

TITLE (ENGLISH):

PCTFULL COPYRIGHT 2006 Univentio on STN  
2002070741 PCTFULL ED 20020926 EW 200237  
METHODS, SYSTEMS AND COMPUTER PROGRAM PRODUCTS FOR  
DETERMINING THE BIOLOGICAL EFFECT AND/OR ACTIVITY OF  
DRUGS, CHEMICAL SUBSTANCES AND/OR PHARMACEUTICAL  
COMPOSITIONS BASED ON THEIR EFFECT ON THE METHYLATION  
STATUS OF THE DNA

TITLE (FRENCH):

PROCEDES, SYSTEMES ET PRODUITS PROGRAMMES INFORMATIQUES  
PERMETTANT DE DETERMINER L'EFFET BIOLOGIQUE ET/OU  
L'ACTIVITE DE MEDICAMENTS, DE SUBSTANCES CHIMIQUES  
ET/OU DE COMPOSITIONS PHARMACEUTIQUES, SUR LA BASE DE  
LEUR EFFET SUR L'ETAT DE METHYLATION DE L'ADN

INVENTOR(S):

OLEK, Alexander, Schroederstrasse 13/2, 10115 Berlin,  
DE;

PATENT ASSIGNEE(S):

BERLIN, Kurt, Marienkaeferweg 4, 14532 Stahnsdorf, DE  
EPIGENOMICS AG, Kastanienallee 24, 10435 Berlin, DE  
[DE, DE]

AGENT:

SCHOHE, Stefan\$, Boehmert & Boehmert,  
Pettenkoferstrasse 20-22, 80336 Muenchen\$, DE

LANGUAGE OF FILING:

English

LANGUAGE OF PUBL.:

English

DOCUMENT TYPE:

Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2002070741	A2	20020912

# DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR  
CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID  
IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD  
MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI

RW (ARIPO):	SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW
RW (EAPO):	GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EPO):	AM AZ BY KG KZ MD RU TJ TM
	AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
	TR
RW (OAPI):	BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
APPLICATION INFO.:	WO 2002-EP2254                      A    20020301
PRIORITY INFO.:	US 2001-60/272,484                  20010301

  

L11      ANSWER 3 OF 5	PCTFULL    COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER:	2002057414 PCTFULL    ED 20020801    EW 200230
TITLE (ENGLISH):	LEUKOCYTE EXPRESSION PROFILING
TITLE (FRENCH):	EVALUATION DU NIVEAU D'EXPRESSION LEUCOCYTAIRE
INVENTOR(S):	WOHLGEMUTH, Jay, 664 Hamilton Avenue, Palo Alto, CA 94301, US [US, US]; FRY, Kirk, 2604 Ross Road, Palo Alto, CA 94303, US [US, US]; MATCUK, George, 141C Escondido Village, Stanford, CA 94305, US [US, US]; ALTMAN, Peter, 717 Evelyn Avenue, Albany, CA 94706, US [US, US]; PRENTICE, James, 120 Dolores Street, San Francisco, CA 94103, US [US, US]; PHILLIPS, Julie, 1090 Mirador Terrace, Pacifica, CA 94044, US [US, US]; LY, Ngoc, 2000 Crystal Springs Road 15-14, San Bruno, CA 94066, US [US, US]; WOODWARD, Robert, 1828 Rheem Court, Pleasanton, CA 94588, US [US, US]; QUERTERMOUS, Thomas, 44 El Rey Road, Portola Valley, CA 94028, US [US, US]; JOHNSON, Frances, 44 El Rey Road, Portola Valley, CA 94028, US [US, US]
PATENT ASSIGNEE(S):	BIOCARDIA, INC., 384 Oyster Point Boulevard, #4, South San Francisco, CA 94080, US [US, US], for all designates States except US; WOHLGEMUTH, Jay, 664 Hamilton Avenue, Palo Alto, CA 94301, US [US, US], for US only; FRY, Kirk, 2604 Ross Road, Palo Alto, CA 94303, US [US, US], for US only; MATCUK, George, 141C Escondido Village, Stanford, CA 94305, US [US, US], for US only; ALTMAN, Peter, 717 Evelyn Avenue, Albany, CA 94706, US [US, US], for US only; PRENTICE, James, 120 Dolores Street, San Francisco, CA 94103, US [US, US], for US only; PHILLIPS, Julie, 1090 Mirador Terrace, Pacifica, CA 94044, US [US, US], for US only; LY, Ngoc, 2000 Crystal Springs Road 15-14, San Bruno, CA 94066, US [US, US], for US only; WOODWARD, Robert, 1828 Rheem Court, Pleasanton, CA 94588, US [US, US], for US only; QUERTERMOUS, Thomas, 44 El Rey Road, Portola Valley, CA 94028, US [US, US], for US only; JOHNSON, Frances, 44 El Rey Road, Portola Valley, CA 94028, US [US, US], for US only
AGENT:	WARD, Michael, R.\$, Morrison & Foerster LLP, 425 Market Street, San Francisco, CA 94105-2482\$, US
LANGUAGE OF FILING:	English
LANGUAGE OF PUBL.:	English
DOCUMENT TYPE:	Patent
PATENT INFORMATION:	

  

NUMBER	KIND	DATE
-----	-----	-----
WO 2002057414	A2	20020725

## DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR  
 CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID  
 IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD  
 MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK  
 SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

RW (ARIPO):

GH GM KE LS MW MZ SD SL SZ TZ UG ZW

RW (EAPO):

AM AZ BY KG KZ MD RU TJ TM

RW (EPO):

AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE  
 TR

RW (OAPI):

BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.:

WO 2001-US47856 A 20011022

PRIORITY INFO.:

US 2000-60/241,994 20001020

US 2001-60/296,764 20010608

L11 ANSWER 4 OF 5

ACCESSION NUMBER:

PCTFULL COPYRIGHT 2006 Univentio on STN

TITLE (ENGLISH):

2000079267 PCTFULL ED 20020515

TITLE (FRENCH):

TREATMENT OF CANCER

INVENTOR(S):

TRAITEMENT ANTICANCEREUX

NIZETIC, Dean;

PATENT ASSIGNEE(S):

GROET, JuergenRP : GILL JENNINGS & EVERY  
 SCHOOL OF PHARMACY, UNIVERSITY OF LONDON;

NIZETIC, Dean;

GROET, Juergen

LANGUAGE OF PUBL.:

English

DOCUMENT TYPE:

Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2000079267	A2	20001228

## DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU  
 CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN  
 IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK  
 MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM  
 TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD  
 SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY  
 DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG  
 CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.:

WO 2000-GB2446 A 20000622

PRIORITY INFO.:

GB 2000-0008161.2 20000403

GB 1999-9914589.8 19990622

L11 ANSWER 5 OF 5

ACCESSION NUMBER:

PCTFULL COPYRIGHT 2006 Univentio on STN

TITLE (ENGLISH):

2000073479 PCTFULL ED 20020515

TITLE (FRENCH):

A COMBINED GROWTH FACTOR-DELETED AND THYMIDINE  
 KINASE-DELETED VACCINIA VIRUS VECTOR

INVENTOR(S):

VECTEUR DU VIRUS DE LA VACCINE COMBINANT DELETION DU  
 FACTEUR DE CROISSANCE ET DELETION DE THYMIDINE KINASE

MCCART, J., Andrea;

BARTLETT, David, L.;

PATENT ASSIGNEE(S):

MOSS, BernardRP : NATAUPSKY, Steven, J.  
 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as  
 represented by THE SECRETARY, DEPARTMENT OF HEALTH AND  
 HUMAN SERVICES;

MCCART, J., Andrea;

BARTLETT, David, L.;

MOSS, Bernard

LANGUAGE OF PUBL.:

English

DOCUMENT TYPE:

Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2000073479	A1	20001207

## DESIGNATED STATES



W: AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ  
DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS  
JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN  
MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT  
TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ  
TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK  
ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM  
GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2000-US14679 A 20000526  
PRIORITY INFO.: US 1999-60/137,126 19990528

=> d l11 ibib kwic 2

L11 ANSWER 2 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN  
ACCESSION NUMBER: 2002070741 PCTFULL ED 20020926 EW 200237  
TITLE (ENGLISH): METHODS, SYSTEMS AND COMPUTER PROGRAM PRODUCTS FOR  
DETERMINING THE BIOLOGICAL EFFECT AND/OR ACTIVITY OF  
DRUGS, CHEMICAL SUBSTANCES AND/OR PHARMACEUTICAL  
COMPOSITIONS BASED ON THEIR EFFECT ON THE METHYLATION  
STATUS OF THE DNA  
TITLE (FRENCH): PROCEDES, SYSTEMES ET PRODUITS PROGRAMMES INFORMATIQUES  
PERMETTANT DE DETERMINER L'EFFET BIOLOGIQUE ET/OU  
L'ACTIVITE DE MEDICAMENTS, DE SUBSTANCES CHIMIQUES  
ET/OU DE COMPOSITIONS PHARMACEUTIQUES, SUR LA BASE DE  
LEUR EFFET SUR L'ETAT DE METHYLATION DE L'ADN  
INVENTOR(S): OLEK, Alexander, Schroederstrasse 13/2, 10115 Berlin,  
DE;  
PATENT ASSIGNEE(S): BERLIN, Kurt, Marienkaefeweg 4, 14532 Stahnsdorf, DE  
EPIGENOMICS AG, Kastanienallee 24, 10435 Berlin, DE  
[DE, DE]  
AGENT: SCHOHE, Stefan\$, Boehmert & Boehmert,  
Pettenkoferstrasse 20-22, 80336 Muenchen\$, DE  
LANGUAGE OF FILING: English  
LANGUAGE OF PUBL.: English  
DOCUMENT TYPE: Patent  
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2002070741	A2	20020912

# DESIGNATED STATES

W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR  
CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID  
IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD  
MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI  
SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW  
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW  
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM  
RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE  
TR  
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2002-EP2254 A 20020301  
PRIORITY INFO.: US 2001-60/272,484 20010301

DETD . . . since in most of the cases an effective  
drug/treatment has to be found very rapidly,  
Furthermore, such developments currently involve very cost-intensive  
screening procedures  
until a particularly suited compound (often called Jead&quot;-cornpound)  
is found which could  
then serve as a chemical basis for an effective treatment.  
of course, alternative  
treatments for already known diseases. Furthermore, the need exists for  
a reliable, cost-

effective, fast and automatable method for screening such new effective compounds.

## 2. Screening for new biologically active compounds using ,combinatorial chemistry"

The method of combinatorial chemistry is described as a profound change in the. . . AT, et

al. ,Search and discovery strategies for biotechnology: the paradigm shift." Microbiol Mol

Biol Rev 2000 Sep;64(3):573-606)

In general, combinatorial chemistry involves screening of a specific (or a set of specific)

compound with a vast number of potential biological candidate substances for example, pro-

p  
teins) that might interact with the compound. Interacting partners are selected and used for

further screening. Initially screened and isolated

compounds can be used as lead"-

compounds for the development of biologically active compounds.useful for treatment of dis-eases.

potential utility for the treatment of

conditions involving cerebral hypoxia." Life Sci 2000 Aug 1

1;67(12):1389-96) describe the

use of HTS (high-throughput screening) libraries for

reevaluation of the pharmacologic prop-

erties of substances such as extract from the leaves of Ginkgo biloba Linne (form.. . .

Although the method of combinatorial chemistry exhibits several advantages in comparison to

conventional methods for screening for biologically effective

compounds which are useful for

the development of new medicaments, there are still several drawbacks associated with this method.

The screening of a combinatorial chemistry library involves a screening for a multitude of

different possible reactions and/or interactions of the compounds to be analysed with the in-

teracting partners. Therefore, the reaction conditions are assumed crucial for the result of the

screening. In particular, a compound which shows an

interaction with a target in such a com-

binatorial assay in vitro might exhibit. . . prediction of an

effective compound very difficult and unreliable. As a result, an inter-

action in an in vitro combinatorial chemistry screening assay

can always only give a hint for a

potential biological function of the screened compound in

vivo.

As a result, combinatorial chemistry screening involves a

necessary second step; once a po-

tential target/lead compound has been identified/found, the

biological effect still has to be

confirmed/determined in an in vivo context. This makes compound

identification using this

method unpredictable, slow and costly.

only individual regions

up to approximately 3000 base pairs in length have been examined, and an overall examina-

tion of cells to identify thousands of possible methylation events is not- possible. However, this method is not capable of reliably analyzing minute fragments from small. . .

Burkitt's lym-

phoma: molecular analysis of primary tumor tissue; Blood 1998 Feb 15;91(4):13 73-8 1)

- Wilms tumor (Kleyanova EV et al. "Identification of a tumor-specific methylation site in

the Wilms tumor suppressor gene; Oncogene 1998 Feb 12;16(6):713-20)

- Prader-Willi/Angelman syndrome (Zeschnigh et al. "Imprinted. .

The. present invention uses the modifications in the methylation pattern of the DNA for

screening of biologically effective substances. In general, the invention uses the fact that the biological effect of a potentially biologically effective drug,. . .

The invention has several advantages in comparison to other.

screening methods, in particular combinatorial chemistry. First, the reaction conditions of the drug, chemical substance or pharmaceutical composition with the biological test system. . .

Second, the analysis of the methylation pattern of the DNA allows screening of the in vivo effect of the substance in a one-step procedure using one controllable reaction (namely, the bisulfite treatment in order. . .

Thirdly, screening for potential lead-compounds becomes less time consuming and less costly, since the complete screening and analysis procedure can be automated.

Fourth, the inventive method allows the inclusion of personal data into the selection/analysis procedure which allows for a personalised screening of drugs, chemical substances or pharmaceutical compositions.

In a further preferred method according to the invention, the biological samples A and B are obtained from the identical individual, tissue, cell or other biological material.

or

pharmaceutical composition. This allows the use of the inventive method to monitor and/or

modify an already employed treatment regimen and to screen for unwanted side effects of the initially employed drugs, chemical substances or pharmaceutical compositions which leads to a strictly ,personalised" medicament. . .

cytosine methylation sites

is analysed in parallel. The analysis of a multitude of sites in parallel allows for both an effective screening and a statistically highly relevant result of the method.

one to directly connect

the tested drug, chemical substance or pharmaceutical composition with

an effect on those genes and therefore allow the identification of possibly valuable new lead compounds as well as therapeutically important compounds.

In one embodiment, the method of the invention is characterised in that the identical biological sample, different biological samples or a combination thereof is used in steps a) and/or b).

#### Example 2

##### Screening of a peptide library

A peptide library was prepared in a 96-well culture plate which contained overlapping peptide fragments derived from the . . .

micro arrays representing 256 CpG

and the methylation statuses of the CpGs were analysed according to a method described in Example 3

##### Screening of a fractionated plant crude extract

In order to analyse the anti-metastatic effect of *Celosia argentea* seed extracts (CAE), which have traditionally. . .

(CD47 anti-gen (Rh-related antigen, integrin-associated signal transducer); CD48 (CD48 antigen (B-cell membrane protein); CD53 (CD53 antigen); CD59 (CD59 antigen p18-20 (antigen identified by monoclonal antibodies 16.3A5, EJ16, EBO, EL32 and G344); CD63 (CD63 antigen (melanoma I antigen); CD68 (CD68 antigen); CD7 (CD7 antigen. . . LAMA4 (Laminin, alpha 4); LAMA5 (Laminin, alpha 5); LY64 (Lymphocyte antigen 64 (mouse) homolog, radioprotective, 105kD); LYZ (Lysozyme (renal amyloidosis)); MDUI (Antigen identified by monoclonal antibodies 4F2, TRAI.10, TROP4, and T43); MET (Met proto-oncogene (hepatocyte growth factor receptor)); MIC2 (Antigen identified by monoclonal antibodies 12E7, F21 and 013); MICA (MHC class I polypeptide-related sequence A); MME (Membrane metallo-endopeptidase (neutral endopeptidase, enkephalinase,. . .

I (BCL2-related)); MCM4 (Minichromosome maintenance deficient (*S. cerevisiae*) 4); MEKK3 (MAP/ERK kinase kinase 3); MEKK5 (MAP/ERK kinase kinase 5); MKI67 (Antigen identified by monoclonal antibody Ki-67); MSTIR (Macrophage stimulating 1 receptor (c-met-related tyrosine kinase)); NCK1 (NCK adaptor protein 1); NEK3 (NIMA (never. . .

of split);

AFD I (Acrofacial dysostosis 1, Nager type); AGC I (Aggrecan I (chondroitin sulfate proteoglycan 1, large aggregating proteoglycan, antigen identified by monoclonal antibody AO 1 22));

AH02 (Albright hereditary osteodystrophy-2); A1113 (Amelogenesis imperfecta 3, hypoplasia-ratio or hypoplastic type); ALX3 (Aristaless-like homeobox. . .

related

to AF4); LYL1 (Lymphoblastic, leukemia derived sequence 1); MAFG (V-maf musculoaponeurotic fibrosarcoma (avian) oncogene family, protein G); MAX (MAX protein); MDM2 (Mouse double minute 2, human homolog of; p53-binding protein); MHC2TA (MHC class II transactivator); MKI67 (Antigen identified by monoclonal antibody Ki-67); MNDA (Myeloid cell nuclear differentiation antigen); MSXI (Msh (Drosophila) homeo box homolog I (formerly homeo box 7));. . .

integrin-associated signal transducer)); CD5 (CD5 antigen (p56-62)); CD53 (CD53 antigen); CD58 (CD58 antigen, (lymphocyte function-associated antigen 3)); CD59 (CD59 antigen p18-20 (antigen identified by monoclonal antibodies 16.3A5, EJ16, EJ30, EL32 and G344)); CD5L (CD5 antigen-like (scavenger receptor cysteine rich family)); CD6 (CD6 antigen);. . .

LYN (V-yes-1 Yamaguchi sarcoma viral related oncogene homolog); LYZ (Lysozyme (renal amyloidosis))- , MISI (Membrane component, chromosome 1, surface marker I (400 glycoprotein, identified by monoclonal antibody GA733)); MAB21L1 (Mab-21 (C. elegans)-like 1); MACAMI (Mucosal addressin cell adhesion molecule-1); MADHI (MAD (mothers against decapentaplegic, Drosophila). . . MCC (Mutated in colorectal cancers); MCF2 (MCF.2 cell line derived transforming sequence); MCP (Membrane cofactor protein (CD46, trophoblast-lymphocyte cross-reactive antigen)); MDF1 (Antigen identified by monoclonal antibody A-3A4); MDH2 (Malate dehydrogenase 2, NAD (mitochondrial)); MDUI (Antigen identified by monoclonal antibodies 4172, TRALIO, TROP4, and T43); MEI (Malic enzyme 1, soluble); ME2 (Malic enzyme 2, mitochondrial); MEKKI (MAP/ERK kinase kinase. . . MEMOI (Methylation modifier for class I HLA); MENI (Multiple endocrine neoplasia 1); MEPIA (Meprin A, alpha (PABA peptide hydrolase)); MER2 (Antigen identified by monoclonal antibodies 1D12, 2177); MFAP2 (Microfibrillar-associated protein 2); MFAP4 (Microfibrillar-associated protein 4); MFTS (Migraine, familial typical, susceptibility to); MGCT (MGI); MGP (Matrix Gla protein); MHC2TA (MHC class II transactivator); MIC2 (Antigen identified by monoclonal antibodies 12E7, F21 and 013); MI C5 (Antigen identified by monoclonal antibody RI); MIC7 (Antigen identified by monoclonal antibody 28 7); MICA (MHC class I polypeptide-related sequence A); MIF (Macrophage migration inhibitory factor (glycosylation-inhibiting factor)); MIG (Monokine induced. . .

(Uridine phosphorylase); UPK1B (Uroplakin 113); UROD (Uroporphyrinogen decarboxylase); UROS (Uroporphyrinogen III synthase (congenital erythropoietic porphyria)); USH2A (Usher syndrome 2A (autosomal recessive,

mild)); USP7 (Ubiquitin specific protease 7 (herpes virus-associated)); VASP (Vasodilator-stimulated phosphoprotein); VCAM I (Vascular cell adhesion molecule 1); VDAC I (Voltage-dependent anion. . .

CD48 (CD48 antigen (B-cell membrane protein)); CD53 (CD53 antigen); CD58 (CD58 antigen, (lymphocyte function-associated antigen 3)); CD59 (CD59 antigen p18-20 (antigen identified by monoclonal antibodies 16.3A5, EJ16, EJ30, EL32 and G344)); CD63 (CD63 antigen (melanoma 1 antigen)); CD68 (CD68 antigen); CD7 (CD7 antigen. . . gene 3); LY64 (Lymphocyte antigen 64 (mouse) homolog, radioprotective, 105kD); LYZ (Lysozyme (renal amyloidosis)); MAPIB (Microtubule-associated protein 113); MDUI (Antigen identified by monoclonal antibodies 4172, TRALIO, TROP4, and T43); MIC2 (Antigen identified by monoclonal antibodies 12E7, F21 and 013); MICA (MHC class I polypeptide-related sequence A); MME (Membrane metallo-endopeptidase (neutral endopeptidase, enkephalinase, CALLA,. . .

melanogaster muscleblind B protein); MDM2 (Mouse double minute 2, human homolog of, p53-binding protein); MHC2TA (MHC class II transactivator); MKI67 (Antigen identified by monoclonal antibody Ki-67); MNDA (Myeloid cell nuclear differentiation antigen); MSX1 (Msh (Drosophila) homeo box homolog 1 (formerly homeo box 7)); MTHFD. .

member 3)); LYN (V-src-1 Yamaguchi sarcoma viral related oncogene homolog); MIS I (Membrane component, chromosome 1, surface marker I (40kD glycoprotein, identified by monoclonal antibody GA733)); M4SI (Membrane component, chromosomal 4, surface marker (35kD glycoprotein)); MADH4 (MAD (mothers against decapentaplegic, Drosophila) homolog. . . oncogene: family, protein K); MASI (MASI oncogene); MAX (MAX protein); MCC (Mutated in colorectal cancers); MCF2 (MCF.2 cell line derived transforming sequence); MDM2 (Mouse double minute 2, human homolog of-, p53-binding protein); MEL (Mel transforming oncogene (derived from cell line NK14)- RAB8 homolog); MELLI (Mel. . . member 1)); LTB (Lymphotoxin beta (TNF superfamily, member 3)); MIS I (Membrane component, chromosome 1, surface marker I (40kD glycoprotein, identified by monoclonal antibody GA733)); M4SI (Membrane component, chromosomal 4, surface marker (35kD glycoprotein)); MADH4. (MAD (mothers against decapentaplegic, Drosophila) homolog 4);. . .

CLMEN. . . according to any of claims 1 to 4, characterised in that the biological samples A and B are obtained from the identical individual, tissue, cell or other biological material.  
. Method according claim 5, characterised in that the biological samples A. and B. . .

28 Method according to any of claims I to 27, characterised in that the identical biological sample, different biological samples or a combination thereof is used in steps a) and/or b).

=> d his

(FILE 'HOME' ENTERED AT 15:06:58 ON 20 SEP 2006)

FILE 'CAPLUS' ENTERED AT 15:07:09 ON 20 SEP 2006

L1 21 S HAUSP AND MDM2  
L2 6 S L1 NOT PY>2004  
L3 40 S USP7  
L4 8 S L3 AND MDM2

FILE 'PCTFULL' ENTERED AT 15:12:56 ON 20 SEP 2006

L5 37 S USP7  
L6 34 S HAUSP  
L7 59 S L6 OR L5  
L8 18 S MDM2 AND L7  
L9 532010 S SCREEN? OR IDENT?  
L10 18 S L9 AND L8  
L11 5 S L10 NOT PY>2002

FILE 'REGISTRY' ENTERED AT 15:17:14 ON 20 SEP 2006

E "HAUSP"/CN 25  
L12 1 S E4  
E "USP7"/CN 25  
E "USP 7"/CN 25  
E "USP-7"/CN 25

FILE 'MEDLINE' ENTERED AT 15:19:32 ON 20 SEP 2006

L13 39 S HAUSP OR (USP () 7)  
L14 55 S HAUSP OR (USP7)  
L15 2699 S MDM2  
L16 18 S L15 AND L14  
L17 1 S L16 NOT PY>2002

FILE 'PCTFULL' ENTERED AT 15:24:49 ON 20 SEP 2006

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

41.66

99.85

FILE 'CAPLUS' ENTERED AT 15:38:39 ON 20 SEP 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Sep 2006 VOL 145 ISS 13

FILE LAST UPDATED: 19 Sep 2006 (20060919/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.  
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> d ibib abs 12 6

L2 ANSWER 6 OF 6 CAPLUS. COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2002:312567 CAPLUS  
DOCUMENT NUMBER: 137:44608  
TITLE: Deubiquitination of p53 by HAUSP is an  
important pathway for p53 stabilization  
AUTHOR(S): Li, Muyang; Chen, Delin; Shiloh, Ariel; Luo, Jianyuan;  
Nikolaev, Anatoly Y.; Qin, Jun; Gu, Wei  
CORPORATE SOURCE: Institute for Cancer Genetics, and Department of  
Pathology, College of Physicians b Surgeons, Columbia  
University, New York, NY, 10032, USA  
SOURCE: Nature (London, United Kingdom) (2002), 416(6881),  
648-652  
CODEN: NATUAS; ISSN: 0028-0836  
PUBLISHER: Nature Publishing Group  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB The p53 tumor suppressor is a short-lived protein that is maintained at low levels in normal cells by Mdm-mediated ubiquitination and subsequent proteolysis. Stabilization of p53 is crucial for its tumor suppressor function. However, the precise mechanism by which ubiquitinated p53 levels are regulated in vivo is not completely understood. By mass spectrometry of affinity-purified p53-associated factors, the authors have identified herpesvirus-associated ubiquitin-specific protease (HAUSP) as a novel p53-interacting protein. HAUSP strongly stabilizes p53 even in the presence of excess Mdm2, and also induces p53-dependent cell growth repression and apoptosis. Significantly, HAUSP has an intrinsic enzymic activity that specifically deubiquitinates p53 both in vitro and in vivo. In contrast, expression of a catalytically inactive point mutant of HAUSP in cells increases the levels of p53 ubiquitination and destabilizes p53. These findings reveal an important mechanism by which p53 can be stabilized by direct deubiquitination and also imply that HAUSP might function as a tumor suppressor in vivo through the stabilization of p53.

REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	3.66	103.51
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-0.75	-0.75

STN INTERNATIONAL LOGOFF AT 15:39:51 ON 20 SEP 2006